<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664155</url>
  </required_header>
  <id_info>
    <org_study_id>1508189</org_study_id>
    <secondary_id>2016-000858-35</secondary_id>
    <nct_id>NCT02664155</nct_id>
  </id_info>
  <brief_title>Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants</brief_title>
  <acronym>VERDICT</acronym>
  <official_title>Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC)&#xD;
      anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is&#xD;
      associated with an increased risk of thromboembolic and bleeding complications compared to&#xD;
      patients with normal renal function. Direct oral anticoagulants (DOAs) have been shown to be&#xD;
      at least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate&#xD;
      renally impaired patients were poorly represented and patients with severe renal&#xD;
      insufficiency not at all. So no dose reduction was considered.&#xD;
&#xD;
      Surprisingly, DOAs have been approved for VTE treatment in moderate and severe renally&#xD;
      impaired patients. There is need to evaluate a reduced dose of DOAs for VTE treatment in&#xD;
      patients with moderate and severe renal insufficiency.&#xD;
&#xD;
      We plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE&#xD;
      patients with moderate or severe renal insufficiency in terms of net clinical benefit&#xD;
      (recurrent VTE and major bleeding) at 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC)&#xD;
      anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is&#xD;
      associated with an increased risk of thromboembolic and bleeding complications compared to&#xD;
      patients with normal renal function. These patients represent more than 20% of the VTE&#xD;
      population in clinical practice. Direct oral anticoagulants (DOAs) have been shown to be at&#xD;
      least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate&#xD;
      renally impaired patients were poorly represented (&lt;10%) and patients with severe renal&#xD;
      insufficiency not at all. So no dose reduction was considered.&#xD;
&#xD;
      The new DOAs have also been developed for stroke prevention in atrial fibrillation (SPAF).&#xD;
      Patients including in AF trials are generally older and more prone to present renal&#xD;
      impairment (&gt;20%) than in VTE trials. So a reduced dose of DOAs was evaluated and shown to be&#xD;
      at least as effective as, and safer than VKA in the subgroup of patients with moderate renal&#xD;
      insufficiency (creatinine clearance between 30 to 50 ml/min).&#xD;
&#xD;
      Surprisingly, DOAs have been approved for VTE treatment and SPAF in moderate and severe&#xD;
      renally impaired patients (creatinine clearance between 15 to 30 mL/min). Moreover, patients&#xD;
      have to receive a reduced dose of DOAs for SPAF but a full dose of DOAs for VTE that could be&#xD;
      associated with an increased bleeding risk, as suggested by some subgroup analyses. So,&#xD;
      there, there is need to evaluate a reduced dose of DOAs for VTE treatment in patients with&#xD;
      moderate and severe renal insufficiency (creatinine clearance between 15 to 50 mL/min).&#xD;
&#xD;
      Apixaban and rivaroxaban appear to be the best candidates since:&#xD;
&#xD;
        -  both are approved in France in VTE patients&#xD;
&#xD;
        -  they have mixed pathway of elimination (hepatic and renal)&#xD;
&#xD;
        -  they have several other pharmacological similarities and they respective clinical trials&#xD;
           have shown similar efficacy and safety profiles when compared with SOC for VTE&#xD;
           treatment.&#xD;
&#xD;
        -  they do not need to be preceded by initial parenteral heparins on the contrary to&#xD;
           dabigatran and edoxaban. This allows evaluating the impact of DOAs in renally impaired&#xD;
           patients independently from the initial heparins effect&#xD;
&#xD;
        -  a reduced dose regimen is available and approved in AF&#xD;
&#xD;
        -  the evaluation of 2 DAOs allows evaluating the concept of this new class in renally&#xD;
           impaired VTE patients independently from the pharmaceutical companies.&#xD;
&#xD;
      Finally we plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC&#xD;
      in VTE patients with moderate or severe renal insufficiency in terms of net clinical benefit&#xD;
      (recurrent VTE and major bleeding) at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority of reduced doses of DOAs</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate that reduced doses of DOAs (rivaroxaban or apixaban) are non-inferior to standard of care (heparins/VKA) on the net clinical benefit (recurrent VTE and major bleeding) in renally impaired patients suffering from an acute VTE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate the non--inferiority of reduced dose of DOAs on the risk of major bleedings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism (VTE) events</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate the non--inferiority of reduced dose of DOAs on the risk of recurrent VTE.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:&#xD;
Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months&#xD;
Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Direct Oral Anticoagulant</description>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <other_name>Eliquis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Direct Oral Anticoagulant</description>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <other_name>Xarelto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Standard Of Care</description>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA</intervention_name>
    <description>Standard Of Care</description>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
    <other_name>vitamin K antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a moderate renal insufficiency defined by a creatinine clearance between&#xD;
             30 to 50 ml/min (Cockcroft and Gault formulae) or a severe renal insufficiency&#xD;
             (between 15 to 29 ml/min)&#xD;
&#xD;
          -  Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis&#xD;
             (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis), planned to be&#xD;
             treated for at least 3 months&#xD;
&#xD;
          -  Patients &gt;18 years&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for anticoagulants other than VTE&#xD;
&#xD;
          -  Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a&#xD;
             systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more&#xD;
             than 110 mm Hg&#xD;
&#xD;
          -  Anticoagulation for more than 72 hours prior to randomization&#xD;
&#xD;
          -  Chronic liver disease or chronic hepatitis&#xD;
&#xD;
          -  Patient at high risk of bleeding&#xD;
&#xD;
          -  Creatinine clearance &lt;15 ml/min or end stage renal disease or indication for&#xD;
             extra-renal dialysis&#xD;
&#xD;
          -  Need for concomitant anti-platelet therapy other than aspirin 75-325 mg per day.&#xD;
             However concomitant treatment with aspirin is discouraged in this population at&#xD;
             bleeding risk.&#xD;
&#xD;
          -  Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a&#xD;
             protease inhibitor for human immunodeficiency virus infection or azole-antimycotics&#xD;
             agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer&#xD;
             (e.g., rifampin, carbamazepine, or phenytoin),&#xD;
&#xD;
          -  Active pregnancy or expected pregnancy or no effective contraception&#xD;
&#xD;
          -  Any contraindication listed in the local labeling of UFH, LMWH or VKA or oral&#xD;
             anticoagulant.&#xD;
&#xD;
          -  Cancer-associated VTE requiring long-term treatment with LMWH&#xD;
&#xD;
          -  Life expectancy of less than 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MISMETTI Patrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MISMETTI Patrick, MD</last_name>
    <phone>04 77 12 02 85</phone>
    <phone_ext>+33</phone_ext>
    <email>patrick.mismetti@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LABRUYERE Carine, CRA</last_name>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH ARRAS</name>
      <address>
        <city>Arras</city>
        <state>Boulevard Georges Besnier</state>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro AQUILANTI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandro AQUILANTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan GREBET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abed RIFAI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <state>Hôpital Trousseau</state>
        <zip>37550</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis ANGOULVANT, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Denis ANGOULVANT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe SAINT ETIENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Agen-Nérac</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert TRINH-DUC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Albert TRINH-DUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Antoinette SEVESTRE-PIETRI, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Antoinette SEVESTRE-PIETRI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon SOUDET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie ROY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Marie ROY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas MOUMNEH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent AZZOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine DOUILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel LE MOIGNO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MENNEVEAU, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MENNEVEAU, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno GENET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël CONSTANS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joël CONSTANS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie SKOPINSKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Cavale Blanche Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norbert ANDRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nolwenn ASTRUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude BARNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie BAZIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire DE MOREUIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc DE SAINT-MARTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien DELLUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique MOTTIER, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile TROMEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle GOURVIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe LEROYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël LE MAO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine LACUT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwénolé ROHEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gwénolé ROHEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie RIVIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc DANGUY DES DESERTS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire ROUSSEAU LEGRAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier PROTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence HEMON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Castelnau-le-Lez</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique BRISOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique BRISOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Louis Pasteur - Chartres</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandrine BAYLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catérina LOGHIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cliff KHALIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck ALBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madalina DASOVEANU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud DEMICHELI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Téodora DUTOIU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent ROUSSEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé GORKA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre SOCIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot SCHMIDT, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jeannot SCHMIDT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine GIROUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MATHEVON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DUBLANCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone HEUSER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine BREUIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed HADJ-ABDELKADER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise SORTAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas FALVO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas FALVO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérik LEDAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léo FRECHIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Tronche Grenoble</name>
      <address>
        <city>Grenoble 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles PERNOD, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles PERNOD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Foix - APHP Ivry sur Seine</name>
      <address>
        <city>Ivry sur Seine</city>
        <zip>94200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric PAUTAS, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eric PAUTAS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe LACROIX, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe LACROIX, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire GRANGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire GRANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène DESMURS-CLAVEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hélène DESMURS-CLAVEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Audrey DUREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali AUBINEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith CATELLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle QUERE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle QUERE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital Bellier</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal CHEVALET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal CHEVALET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure DE DECKER, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Hélène FIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Sophie BOUREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume CHAPELET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Typhaine RIAUDEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaële BACHTARZI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny PESLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony DYLIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie BONNETIER PICHIERRI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte MASCART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique EL KOURI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique EL KOURI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo DE CARVALHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle GUEFFET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure PAVAGEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas GOFFINET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline BLAISE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah-Lou GUYOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven LAURENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile DURANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme CONNAULT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni GAUTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier ESPITIA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion BAZILE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chloé CHEVALIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre GALLAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie GUITTET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony PATRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadège TOSTAIN-HENOC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile FERRARI, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Emile FERRARI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP - APHP Paris</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy MEYER, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Guy MEYER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan MAREY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amira BENATTIA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin PLANQUETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne ROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean PASTRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier SANCHEZ, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien CLERC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier- APHP Paris</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MAHE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle MAHE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline FOURGEAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime DELRUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis JOURNEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine POENOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic PLAISANCE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ygal BENHAMOU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ygal BENHAMOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MISMETTI, MD PhD</last_name>
      <phone>04 77 12 02 85</phone>
      <phone_ext>+33</phone_ext>
      <email>patrick.mismetti@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MISMETTI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BERTOLETTI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine ACCASSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MOULIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile DUVILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie DE MAGALHES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andréa BUCHMULLER-CORDIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique STEPHAN, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique STEPHAN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena-Mihaela CORDEANU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien GAERTNER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie FALLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ELIAS, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine ELIAS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard COLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Noël POGGI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ELIAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anaïs CORNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitri CORNAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline MARTINEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah REZKALLAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA de Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PALEIRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas PALEIRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra BURA-RIVIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra BURA-RIVIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas MOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wassim MOKADDEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie MALLOIZEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel KNAFO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François-Xavier LAPÉBIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas QUEMENEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémentine ROUSSELIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noémie LEGOUELLEC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul GRAGEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal insufficiency</keyword>
  <keyword>Direct oral anticoagulants (DOA)</keyword>
  <keyword>Deep Vein Thrombosis (DVT)</keyword>
  <keyword>Pulmonary Embolism (PE)</keyword>
  <keyword>Venous Thromboembolism (VTE)</keyword>
  <keyword>Heparins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

